Salim Chahin

Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples

Tyler L. Borko, Alanna Ritchie, Sean Selva, Stefan Sillau et autres

Background Interpretation of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels in blood requires reference ranges from healthy cohorts, accounting for demographic features. Objective To compare serum and plasma NfL and GFAP in healthy individuals, accounting for age, sex, …

us, de (code pays fourni par la source)

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study

Alexandra Scharf, Jeffrey A. Cohen, Ruth Ann Marrie, Aaron Miller et autres

BACKGROUND AND OBJECTIVES: The 2024 McDonald criteria allow diagnosis of multiple sclerosis (MS) in individuals presenting with symptoms not specific for MS or incidental imaging findings suggestive of demyelination when supported by biomarker evidence, reflecting a shift toward diagnostic definitions increasingly grounded …

us, ca (code pays fourni par la source)

HPR78 FORMULARY EXCLUSIONS AND NON-ADHERENCE TO DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS IN MEDICARE PART D

MATTHEW KLEBANOFF, Zhi Geng, Pengxiang Li, Salim Chahin et autres

us (code pays fourni par la source)

Medicare Part D Formulary Coverage of Disease-Modifying Therapies for Multiple Sclerosis

P Li, Matthew J. Klebanoff, John K. Lin, Keya D. Doshi et autres

This cohort study examines Medicare Part D formulary coverage of disease-modifying therapies for patients with multiple sclerosis, comparing coverage of brand-name and generic drugs.

us (code pays fourni par la source)

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

Pengxiang Li, John K. Lin, Matthew J. Klebanoff, Riya Palkar et autres

Background and Objectives: The Inflation Reduction Act (IRA) introduced major reforms to Medicare Part D, including an annual out-of-pocket (OOP) maximum and the Medicare Prescription Payment Plan (MPPP), which allows beneficiaries to spread OOP costs over monthly payments. The IRA's Part D …

us (code pays fourni par la source)

Medicare Part D Utilization, Spending, and Formulary Coverage of Brand-name Disease Modifying Therapies with Generics Available for Multiple Sclerosis (P4-1.008)

Pengxiang Li, Matthew J. Klebanoff, John K. Lin, Salim Chahin et autres

To examine Medicare Part D utilization, spending, and formulary coverage of brand-name disease modifying therapies (DMTs) with generics available for multiple sclerosis (MS) in 2022.

us (code pays fourni par la source)

Reducing Out-of-pocket Costs of Disease-modifying Therapies for Medicare Part D Beneficiaries with Multiple Sclerosis: A Call to Action for Neurologists (P3-1.004)

Pengxiang Li, John K. Lin, Matthew J. Klebanoff, Riya Palkar et autres

To estimate out-of-pocket (OOP) costs for disease-modifying therapies (DMTs) among Medicare Part D beneficiaries with multiple sclerosis (MS) under different scenarios.

us (code pays fourni par la source)

Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity

Miguel Tolentino, Francesca Pace, Dana C. Perantie, Robert Mikesell et autres

us (code pays fourni par la source)

Smoking Prevalence and Smoking Cessation Treatment Rates Across the Neurology Outpatient Clinics at a Large Academic Hospital (P2-10.004)

Luis Paixão, Jingling Chen, Nina Smock, J. Reddy et autres

Evaluate the prevalence of smoking and tobacco treatment programs in Neurology subspecialty outpatient clinics at a large academic hospital.

Direct and Indirect Care of Patients With Multiple Sclerosis: Burden on Providers and Impact of Portal Messages

Rola Mahmoud, Katie Callahan, Doug Schell, Suzanne Carron et autres

BACKGROUND: Multiple sclerosis (MS) indirect patient-care time is often underreported and uncompensated. Data on time spent on indirect and direct care by MS providers is lacking. METHODS: A survey was designed to understand the practice patterns among MS providers in the United …

us (code pays fourni par la source)

Obesity, gut microbiota, and multiple sclerosis: Unraveling the connection

Amjad Samara, Claudia Cantoni, Laura Piccio, Anne H. Cross et autres

us, au (code pays fourni par la source)

“Brain age” predicts disability accumulation in multiple sclerosis

Matthew R. Brier, LI Zhuo-cheng, Maria Ly, Helmet T. Karim et autres

OBJECTIVE: Neurodegenerative conditions often manifest radiologically with the appearance of premature aging. Multiple sclerosis (MS) biomarkers related to lesion burden are well developed, but measures of neurodegeneration are less well-developed. The appearance of premature aging quantified by machine learning applied to structural …

us (code pays fourni par la source)